902 related articles for article (PubMed ID: 31841714)
41. The impact of the tumor shrinkage by initial EGFR inhibitors according to the detection of EGFR-T790M mutation in patients with non-small cell lung cancer harboring EGFR mutations.
Yoshimura A; Yamada T; Okura N; Takeda T; Furutani W; Kubota Y; Shiotsu S; Hiranuma O; Nishioka N; Chihara Y; Tamiya N; Kaneko Y; Uchino J; Takayama K
BMC Cancer; 2018 Dec; 18(1):1241. PubMed ID: 30537950
[TBL] [Abstract][Full Text] [Related]
42. The application of real-time PCR technique to detect rare cell clones with primary T790M Substitution of EGFR gene in metastases of non-small cell lung cancer to central nervous system in chemotherapy naive patients.
Powrózek T; Krawczyk P; Jarosz B; Mlak R; Wojas-Krawczyk K; Sawicki M; Stencel D; Trojanowski T; Milanowski J
Pathol Oncol Res; 2014 Oct; 20(4):945-51. PubMed ID: 24789720
[TBL] [Abstract][Full Text] [Related]
43. Number of metastatic organs negatively affects the treatment sequence in patients with EGFR-TKI failure.
Mizuno T; Horinouchi H; Watanabe S; Sato J; Morita R; Murakami S; Goto Y; Kanda S; Fujiwara Y; Yamamoto N; Ohe Y
Thorac Cancer; 2020 Apr; 11(4):1038-1044. PubMed ID: 32077630
[TBL] [Abstract][Full Text] [Related]
44. Intrapatient Molecular and Histologic Heterogeneity After First-generation or Second-generation TKI Therapy of NSCLC Patients: Potential Clinical Impact on Subsequent third-generation TKI Treatment.
Iacono D; Osman GA; Migliorino MR; Grillo L; Remotti D; Nunnari J; Ricciardi S; Rossi A; Mancuso A; Graziano P; Di Lorenzo A; Bronzini M; Signora M; Leone A
Am J Clin Oncol; 2019 Nov; 42(11):845-850. PubMed ID: 31644442
[TBL] [Abstract][Full Text] [Related]
45. Efficacy of nintedanib plus docetaxel in patients with refractory advanced epidermal growth factor receptor mutant lung adenocarcinoma.
Riudavets M; Bosch-Barrera J; Cabezón-Gutiérrez L; Diz Taín P; Hernández A; Alonso M; Blanco R; Gálvez E; Insa A; Mielgo X; Morán T; Ponce S; Roa D; Sánchez JM; Majem M
Clin Transl Oncol; 2021 Dec; 23(12):2560-2567. PubMed ID: 34292495
[TBL] [Abstract][Full Text] [Related]
46. Genomic heterogeneity at baseline is associated with T790M resistance mutations in EGFR-mutated lung cancer treated with the first-/second-generation tyrosine kinase inhibitors.
Menzel M; Kirchner M; Kluck K; Ball M; Beck S; Allgäuer M; Assmann C; Schnorbach J; Volckmar AL; Tay TKY; Goldschmid H; Tan DS; Thomas M; Kazdal D; Budczies J; Stenzinger A; Christopoulos P
J Pathol Clin Res; 2024 Mar; 10(2):e354. PubMed ID: 38284983
[TBL] [Abstract][Full Text] [Related]
47. Genetic Profiling of Non-Small Cell Lung Cancer at Development of Resistance to First- or Second-Generation EGFR-TKIs by CAPP-Seq Analysis of Circulating Tumor DNA.
Otsubo K; Sakai K; Takeshita M; Harada D; Azuma K; Ota K; Akamatsu H; Goto K; Horiike A; Kurata T; Nakagaki N; Nosaki K; Iwama E; Nakanishi Y; Nishio K; Okamoto I
Oncologist; 2019 Aug; 24(8):1022-1026. PubMed ID: 31023862
[TBL] [Abstract][Full Text] [Related]
48. Monitoring of T790M in plasma ctDNA of advanced EGFR-mutant NSCLC patients on first- or second-generation tyrosine kinase inhibitors.
Huang CT; Lin CA; Su TJ; Yang CY; Tsai TH; Hsu CL; Liao WY; Chen KY; Ho CC; Yu CJ
BMC Cancer; 2023 Mar; 23(1):234. PubMed ID: 36915101
[TBL] [Abstract][Full Text] [Related]
49. First-in-Human Phase I Study of AC0010, a Mutant-Selective EGFR Inhibitor in Non-Small Cell Lung Cancer: Safety, Efficacy, and Potential Mechanism of Resistance.
Ma Y; Zheng X; Zhao H; Fang W; Zhang Y; Ge J; Wang L; Wang W; Jiang J; Chuai S; Zhang Z; Xu W; Xu X; Hu P; Zhang L
J Thorac Oncol; 2018 Jul; 13(7):968-977. PubMed ID: 29626621
[TBL] [Abstract][Full Text] [Related]
50. Correlation Analysis between T790M Status and Clinical Characteristics of Patients with EGFR-sensitive Mutation Advanced NSCLC who Progressed after the First Generation and First-line EGFR-TKIs Administration: A Real-world Exploratory Study.
Zhen Y; Xu YB; Deng RY; Li M; Ma MT; Zhou ZG; Meng QJ; Gong YN; Zhao LY; Liu YB
Comb Chem High Throughput Screen; 2024; 27(6):845-853. PubMed ID: 37282652
[TBL] [Abstract][Full Text] [Related]
51. Origin of the T790M mutation and its impact on the clinical outcomes of patients with lung adenocarcinoma receiving EGFR-TKIs.
Dong Y; Zhou Z; Wang J; Ma L; Liu Z; Wang Y; Song J; Zhang S; Che N
Pathol Res Pract; 2019 May; 215(5):946-951. PubMed ID: 30760406
[TBL] [Abstract][Full Text] [Related]
52. Exploring the resistance mechanisms of second-line osimertinib and their prognostic implications using next-generation sequencing in patients with non-small-cell lung cancer.
Lee K; Kim D; Yoon S; Lee DH; Kim SW
Eur J Cancer; 2021 May; 148():202-210. PubMed ID: 33744716
[TBL] [Abstract][Full Text] [Related]
53. Real-world utilization of EGFR TKIs and prognostic factors for survival in EGFR-mutated non-small cell lung cancer patients with brain metastases.
Yu X; Sheng J; Pan G; Fan Y
Int J Cancer; 2021 Sep; 149(5):1121-1128. PubMed ID: 33970485
[TBL] [Abstract][Full Text] [Related]
54. Clinical Factors Predicting Detection of T790M Mutation in Rebiopsy for EGFR-Mutant Non-small-cell Lung Cancer.
Kawamura T; Kenmotsu H; Omori S; Nakashima K; Wakuda K; Ono A; Naito T; Murakami H; Omae K; Mori K; Tanigawara Y; Nakajima T; Ohde Y; Endo M; Takahashi T
Clin Lung Cancer; 2018 Mar; 19(2):e247-e252. PubMed ID: 28866043
[TBL] [Abstract][Full Text] [Related]
55. Clinical utility of liquid biopsy for EGFR driver, T790M mutation and EGFR amplification in plasma in patients with acquired resistance to afatinib.
Oya Y; Yoshida T; Asada K; Oguri T; Inui N; Morikawa S; Ito K; Kimura T; Kunii E; Matsui T; Kubo A; Kato T; Abe T; Tsuda T; Hida T
BMC Cancer; 2021 Jan; 21(1):57. PubMed ID: 33435905
[TBL] [Abstract][Full Text] [Related]
56. Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer.
Ludovini V; Bianconi F; Pistola L; Chiari R; Minotti V; Colella R; Giuffrida D; Tofanetti FR; Siggillino A; Flacco A; Baldelli E; Iacono D; Mameli MG; Cavaliere A; Crinò L
J Thorac Oncol; 2011 Apr; 6(4):707-15. PubMed ID: 21258250
[TBL] [Abstract][Full Text] [Related]
57. Uncommon de novo EGFR
Pang LL; Zhuang WT; Huang YH; Liao J; Li MZ; Lv Y; Zhang L; Fang WF
Lung Cancer; 2024 Apr; 190():107528. PubMed ID: 38461768
[TBL] [Abstract][Full Text] [Related]
58. Clinical Features and Progression Pattern of Acquired T790M-positive Compared With T790M-negative EGFR Mutant Non-small-cell Lung Cancer: Catching Tumor and Clinical Heterogeneity Over Time Through Liquid Biopsy.
Dal Maso A; Lorenzi M; Roca E; Pilotto S; Macerelli M; Polo V; Cecere FL; Del Conte A; Nardo G; Buoro V; Scattolin D; Monteverdi S; Urso L; Zulato E; Frega S; Bonanno L; Indraccolo S; Calabrese F; Conte P; Pasello G
Clin Lung Cancer; 2020 Jan; 21(1):1-14.e3. PubMed ID: 31601525
[TBL] [Abstract][Full Text] [Related]
59. EGFR mutation testing and treatment decisions in patients progressing on first- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors.
Chiang AC; Fernandes AW; Pavilack M; Wu JW; Laliberté F; Duh MS; Chehab N; Subramanian J
BMC Cancer; 2020 Apr; 20(1):356. PubMed ID: 32345265
[TBL] [Abstract][Full Text] [Related]
60. The role of T790M mutation in EGFR-TKI re-challenge for patients with EGFR-mutant advanced lung adenocarcinoma.
Zhang Q; Ke E; Niu F; Deng W; Chen Z; Xu C; Zhang X; Zhao N; Su J; Yang J; Yan H; Wu Y; Zhou Q
Oncotarget; 2017 Jan; 8(3):4994-5002. PubMed ID: 27999211
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
